Large Meta-Analysis of Multiple Cancers Reveals a Common, Compact and Highly Prognostic Hypoxia Metagene
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Genome-Wide Screen of Otosclerosis in Population Biobanks
medRxiv preprint doi: https://doi.org/10.1101/2020.11.15.20227868; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Genome-wide Screen of Otosclerosis in 2 Population Biobanks: 18 Loci and Shared 3 Heritability with Skeletal Structure 4 Joel T. Rämö1, Tuomo Kiiskinen1, Juha Karjalainen1,2,3,4, Kristi Krebs5, Mitja Kurki1,2,3,4, Aki S. 5 Havulinna6, Eija Hämäläinen1, Paavo Häppölä1, Heidi Hautakangas1, FinnGen, Konrad J. 6 Karczewski1,2,3,4, Masahiro Kanai1,2,3,4, Reedik Mägi5, Priit Palta1,5, Tõnu Esko5, Andres Metspalu5, 7 Matti Pirinen1,7,8, Samuli Ripatti1,2,7, Lili Milani5, Antti Mäkitie9, Mark J. Daly1,2,3,4,10, and Aarno 8 Palotie1,2,3,4 9 1. Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of 10 Helsinki, Helsinki, Finland 11 2. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 12 Massachusetts, USA 13 3. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 14 USA 15 4. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA 16 5. Estonian Genome Center, University of Tartu, Tartu, Estonia, Institute of Molecular and Cell Biology, 17 University of Tartu, Tartu, Estonia 18 6. Finnish Institute for Health and Welfare, Helsinki, Finland 19 7. Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland 20 8. -
Four-Dimensional Live Imaging of Apical Biosynthetic Trafficking Reveals a Post-Golgi Sorting Role of Apical Endosomal Intermediates
Four-dimensional live imaging of apical biosynthetic trafficking reveals a post-Golgi sorting role of apical endosomal intermediates Roland Thuenauera,b,1,2, Ya-Chu Hsua, Jose Maria Carvajal-Gonzaleza,3, Sylvie Debordea,4, Jen-Zen Chuanga, Winfried Römerc,d, Alois Sonnleitnerb, Enrique Rodriguez-Boulana,5, and Ching-Hwa Sunga,5 aMargaret M. Dyson Vision Research Institute, Weill Medical College of Cornell University, New York, NY 10065; bCenter for Advanced Bioanalysis Linz, 4020 Linz, Austria; and cInstitute of Biology II, and dBIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany Edited by Keith E. Mostov, University of California School of Medicine, San Francisco, CA, and accepted by the Editorial Board January 17, 2014 (received for review March 11, 2013) Emerging data suggest that in polarized epithelial cells newly is an important regulator of biological processes that require synthesized apical and basolateral plasma membrane proteins apical trafficking, e.g., lumen formation during epithelial tubu- traffic through different endosomal compartments en route to the logenesis (11), apical secretion of discoidal/fusiform vesicles in respective cell surface. However, direct evidence for trans-endo- bladder umbrella cells (12), and apical microvillus morphogenesis somal pathways of plasma membrane proteins is still missing and and rhodopsin localization in fly photoreceptors (13). However, the mechanisms involved are poorly understood. Here, we imaged despite the physiological importance of trans-endosomal traf- the entire biosynthetic route of rhodopsin-GFP, an apical marker in ficking, the underlying mechanisms remain largely unclear. epithelial cells, synchronized through recombinant conditional ag- Previous studies on trans-endosomal trafficking in polarized gregation domains, in live Madin-Darby canine kidney cells using epithelial cells have relied on pulse chase/cell fractionation pro- spinning disk confocal microscopy. -
Functional Role of the C-Terminal Amphipathic Helix 8 of Olfactory Receptors and Other G Protein-Coupled Receptors
International Journal of Molecular Sciences Review Functional Role of the C-Terminal Amphipathic Helix 8 of Olfactory Receptors and Other G Protein-Coupled Receptors Takaaki Sato 1,*, Takashi Kawasaki 1, Shouhei Mine 1 and Hiroyoshi Matsumura 2 1 Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, 1-8-31 Midorioka, Ikeda, Osaka 563-8577, Japan; [email protected] (T.K.); [email protected] (S.M.) 2 College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga 525-8577, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-72-751-8342 Academic Editor: Kathleen Van Craenenbroeck Received: 28 September 2016; Accepted: 14 November 2016; Published: 18 November 2016 Abstract: G protein-coupled receptors (GPCRs) transduce various extracellular signals, such as neurotransmitters, hormones, light, and odorous chemicals, into intracellular signals via G protein activation during neurological, cardiovascular, sensory and reproductive signaling. Common and unique features of interactions between GPCRs and specific G proteins are important for structure-based design of drugs in order to treat GPCR-related diseases. Atomic resolution structures of GPCR complexes with G proteins have revealed shared and extensive interactions between the conserved DRY motif and other residues in transmembrane domains 3 (TM3), 5 and 6, and the target G protein C-terminal region. However, the initial interactions formed between GPCRs and their specific G proteins remain unclear. Alanine scanning mutagenesis of the murine olfactory receptor S6 (mOR-S6) indicated that the N-terminal acidic residue of helix 8 of mOR-S6 is responsible for initial transient and specific interactions with chimeric Gα15_olf, resulting in a response that is 2.2-fold more rapid and 1.7-fold more robust than the interaction with Gα15. -
Open Questions: What About the 'Other' Rho Gtpases?
Ridley BMC Biology (2016) 14:64 DOI 10.1186/s12915-016-0289-7 COMMENT Open Access Open questions: what about the ‘other’ Rho GTPases? Anne J. Ridley Abstract know if they interact with and/or regulate the activity of other family members. Indeed, by studying only RhoA, Rho GTPases have many and diverse roles in cell Rac1 and Cdc42, we are likely to be missing the real physiology, and some family members are very well functions of many GEFs and GAPs because their targets studied, including RhoA, Rac1 and Cdc42. But many in cells are among the other Rho GTPases. are relatively neglected, and fundamental questions Interestingly, four family members—Rnd1, Rnd2, Rnd3 about their mechanisms and functions remain open. and RhoH—are ‘atypical’, in that they are known to be constitutively GTP-bound and do not hydrolyse GTP: much less is known about how these family members Rho GTPases are household names for anyone who are regulated. RhoU and RhoV have high intrinsic GDP/ works on eukaryotic cell migration and their functions GTP exchange rates, so are unlikely to need GEFs for in cell migration, cell division and cell polarity are de- activation but could still be turned off by GAPs [1, 4]. scribed in most textbooks on cell biology. Yet most of For two other members, RhoBTB1 and RhoBTB2, the what we know about Rho GTPases comes from studying Rho domains are quite divergent in sequence from other a small subset of the many different family members, family members and they are unlikely to be regulated by namely RhoA, Rac1 and Cdc42. -
Mutational Mechanisms That Activate Wnt Signaling and Predict Outcomes in Colorectal Cancer Patients William Hankey1, Michael A
Published OnlineFirst December 6, 2017; DOI: 10.1158/0008-5472.CAN-17-1357 Cancer Genome and Epigenome Research Mutational Mechanisms That Activate Wnt Signaling and Predict Outcomes in Colorectal Cancer Patients William Hankey1, Michael A. McIlhatton1, Kenechi Ebede2, Brian Kennedy3, Baris Hancioglu3, Jie Zhang4, Guy N. Brock3, Kun Huang4, and Joanna Groden1 Abstract APC biallelic loss-of-function mutations are the most prevalent also exhibiting unique changes in pathways related to prolifera- genetic changes in colorectal tumors, but it is unknown whether tion, cytoskeletal organization, and apoptosis. Apc-mutant ade- these mutations phenocopy gain-of-function mutations in the nomas were characterized by increased expression of the glial CTNNB1 gene encoding b-catenin that also activate canonical nexin Serpine2, the human ortholog, which was increased in WNT signaling. Here we demonstrate that these two mutational advanced human colorectal tumors. Our results support the mechanisms are not equivalent. Furthermore, we show how hypothesis that APC-mutant colorectal tumors are transcription- differences in gene expression produced by these different ally distinct from APC-wild-type colorectal tumors with canonical mechanisms can stratify outcomes in more advanced human WNT signaling activated by other mechanisms, with possible colorectal cancers. Gene expression profiling in Apc-mutant and implications for stratification and prognosis. Ctnnb1-mutant mouse colon adenomas identified candidate Significance: These findings suggest that colon adenomas genes for subsequent evaluation of human TCGA (The Cancer driven by APC mutations are distinct from those driven by WNT Genome Atlas) data for colorectal cancer outcomes. Transcrip- gain-of-function mutations, with implications for identifying tional patterns exhibited evidence of activated canonical Wnt at-risk patients with advanced disease based on gene expression signaling in both types of adenomas, with Apc-mutant adenomas patterns. -
(12) United States Patent (10) Patent No.: US 9,695.227 B2 Steyaert Et Al
USOO9695227B2 (12) United States Patent (10) Patent No.: US 9,695.227 B2 Steyaert et al. (45) Date of Patent: Jul. 4, 2017 (54) BINDING DOMAINS DIRECTED AGAINST (58) Field of Classification Search GPCRG PROTEIN COMPLEXES AND USES None DERVED THEREOF See application file for complete search history. (56) References Cited (75) Inventors: Jan Steyaert, Beersel (BE); Els Pardon, Lubbeek (BE); Toon U.S. PATENT DOCUMENTS Laeremans, Dworp (BE); Brian 5,721,121 A 2/1998 Etcheverry et al. Kobilka, Palo Alto, CA (US): Soren 2007/OO77597 A1 4/2007 Gilchrist et al. Rasmussen, Frederiksberg (DK); 2007/0231830 A1 10/2007 Gilchrist et al. Sebastian Granier, Menlo Park, CA (US); Roger K. Sunahara, Ann Arbor, FOREIGN PATENT DOCUMENTS MI (US) WO 94.04678 A1 3, 1994 WO 993.7681 A2 7, 1999 (73) Assignees: Vrije Universiteit Brussel, Brussels WO OO43507 A2 T 2000 (BE); VIB VZW, Ghent (BE); The WO O190190 A2 11/2001 Board of Trustees of the Leland WO O2O85945 A2 10, 2002 Stanford Junior Universitv, Palo Alto, WO O3O25O2O A1 3, 2003 CA (US); The Regents of the WO O3035694 A2 5, 2003 WO 2004035614 A1 4/2004 University of Michigan, Ann Arbor, WO 2004.049.794 A2 6, 2004 MI (US) WO 2006086883 A1 8, 2006 WO 2009051633 4/2009 (*) Notice: Subject to any disclaimer, the term of this WO 2009,147.196 A1 12/2009 patent is extended or adjusted under 35 WO 2010043650 A2 4/2010 WO 201OO6674.0 A1 6, 2010 U.S.C. 154(b) by 594 days. WO 2012007593 A1 1, 2012 (21) Appl. -
Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature. -
Itga4 Cldn16 Cldn9 Cldn15 Cldn22 Ocln Esam
Supplementary material J Med Genet Table S1. List of 263 genes included in the AGS-LEUK panel. Axonal Guidance Signaling genes as AGS and Leukocyte transvasation genes as LEUK. List of genes (AGS) List of genes (LEUK) ABLIM1 CLDN11 ACTR3 MMP14 ADAM11 MMP15 ADAM23 CTNNA1 ADAMTS1 ENSG00000130396 ADAMTS4 CLDN6 ADAMTS9 MMP24 ARHGEF15 ARHGAP12 ARHGEF6 DLC1 ARPC1B TIMP2 BDNF RAPGEF3 BMP1 F11R BMP4 CLDN23 BMP6 CLDN8 BMP7 JAM3 CXCL12 CLDN3 CXCR4 ARHGAP8 DPYSL5 ICAM1 EFNA1 MMP16 EFNA5 JAM2 ENPEP CLDN7 EPHA1 TIMP3 EPHA3 VCAM1 EPHA5 CLDN5 EPHA7 MSN EPHB1 NOX3 EPHB2 ACTC1 EPHB4 VAV2 FGFR2 CLDN10 FZD1 RAP1GAP FZD10 VAV3 FZD5 MAPK10 FZD6 CTNNA2 GAB1 CDH5 GLI1 PECAM1 GLI3 CTNND1 GNA14 ITGA4 GNAI1 CLDN16 GNAO1 CLDN9 GNAS CLDN15 GNB4 CLDN22 GNG11 OCLN GNG2 ESAM Gallego-Martinez A, et al. J Med Genet 2019; 0:1–7. doi: 10.1136/jmedgenet-2019-106159 Supplementary material J Med Genet GNG7 ACTB IGF1 CYBA IRS1 CTNNB1 IRS2 MMP9 ITGA3 MAPK14 ITGB1 MAPK11 LIMK1 MAPK12 LIMK2 MAPK13 LINGO1 PRKCB LRRC4C PXN MME BCAR1 MMP11 THY1 MMP2 ARHGAP5 MRAS MYL2 MYL9 MYLPF NFATC4 RAP1A NGFR RAP1B NOTUM VASP NRP1 ACTN4 NTN3 ACTN1 NTRK2 VCL NTRK3 RAPGEF4 PAK3 ITK PAK4 VAV1 PAPPA2 PDGFA PDGFC PIK3CB PIK3R1 PLCE1 PLCH1 PLCH2 PLXNA2 PLXNB1 PLXND1 PPP3CA PRKACB PRKAR2A PRKAR2B PRKCA PRKCZ PRKD3 ROBO2 SDC2 SDCBP Gallego-Martinez A, et al. J Med Genet 2019; 0:1–7. doi: 10.1136/jmedgenet-2019-106159 Supplementary material J Med Genet SEMA3B SEMA3C SEMA3E SEMA3F SEMA4F SEMA4G SEMA5A SEMA6B SEMA6D SEMA7A SHC1 SLIT2 SLIT3 STK36 TUBA4A TUBB2B TUBB4A TUBB4B TUBB6 UNC5C UNC5D ENSG00000165197 WIPF1 WNT3 WNT5A WNT7A WNT7B NTNG1 NTNG2 LRRC4 NTN4 TRPC1 TRPC3 TRPC6 PPP3CB PPP3CC PPP3R1 NFATC2 NFATC3 PTK2 FYN RAC1 CDC42 ABLIM2 NCK1 PAK1 PAK2 Gallego-Martinez A, et al. -
Bacterial Toxins That Target Rho Proteins
Bacterial toxins that target Rho proteins. K Aktories J Clin Invest. 1997;99(5):827-829. https://doi.org/10.1172/JCI119245. Perspective Find the latest version: https://jci.me/119245/pdf Perspectives Series: Host/Pathogen Interactions Bacterial Toxins That Target Rho Proteins Klaus Aktories Institut für Pharmakologie and Toxikologie, Albert-Ludwigs-Universität Freiburg, D-79104 Freiburg i.Br., Germany Not only “big” GTP-binding proteins (heterotrimeric G-pro- ular switches in various signal transduction processes, e.g., Rho teins, elongation factor 2) but also “small” GTPases are targets subfamily proteins participate in control of cell–cell contact, for bacterial protein toxins. In this respect, Rho subfamily pro- integrin signaling, endocytosis, transcriptional activation, pro- teins are of particular importance. These GTPases are ADP- liferation, apoptosis, and cell transformation. Accordingly, nu- ribosylated by Clostridium botulinum C3-like transferases and merous potential Rho-interacting effectors have been de- are monoglycosylated by large clostridial cytotoxins. They ap- scribed, some of which are kinases (e.g., Rho kinase, p60 PAK pear to be the target of Escherichia coli cytotoxic necrotizing kinase, PKN kinase, lipid kinases), and some of which are factors (CNF1, 2)1 and Bordetella dermonecrotic toxin (DNT). adaptor proteins without kinase activity (e.g., WASP, p67 Moreover, Rho proteins seem to be essential for uptake of phox). Several of these processes appear to be important for bacteria into eukaryotic cells. bacteria–host interactions, signal transduction of cells of the immune system, and host defense mechanisms. This is particu- Rho proteins larly evident in the case of Rac and its interaction with Rho proteins (Rho stands for Ras homologous proteins) be- p67phox, which is an essential cofactor for superoxide anion long to the superfamny of Ras proteins (1). -
Antibody-Drug Conjugates: Possibilities and Challenges
Review Article Antibody-Drug Conjugates: Possibilities and Challenges Mohammad-Reza Nejadmoghaddam 1,2, Arash Minai-Tehrani 2, Ramin Ghahremanzadeh 2, Morteza Mahmoudi 1, Rassoul Dinarvand 1,3, and Amir-Hassan Zarnani 4,5,6 1. Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 2. Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran 3. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 4. Department of Immunology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran 5. Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran 6. Immunology Research Center, Iran University of Medical Sciences, IUMS, Tehran, Iran * Corresponding authors: Abstract Rassoul Dinarvand, Pharm D., The design of Antibody Drug Conjugates (ADCs) as efficient targeting agents for tu- PhD., Nanotechnology Research mor cell is still in its infancy for clinical applications. This approach incorporates the Center, Faculty of Pharmacy, Tehran University of Medical antibody specificity and cell killing activity of chemically conjugated cytotoxic agents. Sciences, Tehran, Iran Antibody in ADC structure acts as a targeting agent and a nanoscale carrier to deliv- er a therapeutic dose of cytotoxic cargo into desired tumor cells. Early ADCs encoun- Amir-Hassan Zarnani, D.M.T., Ph.D., Reproductive Immunology tered major obstacles including, low blood residency time, low penetration capacity to Research Center, Avicenna tumor microenvironment, low payload potency, immunogenicity, unusual off-target Research Institute, ACECR, toxicity, drug resistance, and the lack of stable linkage in blood circulation. Although Tehran, Iran extensive studies have been conducted to overcome these issues, the ADCs based Tel: +98 21 64121014, 22432020 Fax: +98 21 66959052, 22432021 therapies are still far from having high-efficient clinical outcomes. -
Allicin Inhibits SARS-Cov-2 Replication and Abrogates The
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.15.444275; this version posted June 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome Authors: Kirstin Mösbauer1,2#, Verena Nadin Fritsch3#, Lorenz Adrian4,5, Jörg Bernhardt6, Martin Clemens Horst Gruhlke7, Alan John Slusarenko7, Daniela Niemeyer1,2 and Haike Antelmann3* Departments & Institutions: 1Institute of Virology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, and Berlin Institute of Health (BIH), Charitéplatz 1, 10117, Berlin, Germany. 2German Centre for Infection Research (DZIF), Berlin, Germany. 3Freie Universität Berlin, Institute for Biology-Microbiology, D-14195 Berlin, Germany 4Department Environmental Biotechnology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany 5 Fachgebiet Geobiotechnologie, Technische Universität Berlin, Germany 6Institute for Microbiology, University of Greifswald, D-17489 Greifswald, Germany 7Department of Plant Physiology, RWTH Aachen University, 52056 Aachen, Germany Running title: Allicin inhibits replication of SARS-CoV-2 in Vero E6 and Calu-3 cells *Corresponding author: Haike Antelmann, Institute for Biology-Microbiology, Freie Universität Berlin, Königin-Luise-Strasse 12-16, D-14195 Berlin, Germany, Tel: +49-(0)30-838-51221, Fax: +49-(0)30-838-451221 E-mail: [email protected] # Authors contributed equally to this work: Kirstin Mösbauer, Verena Nadin Fritsch Key words: SARS-CoV-2/ allicin/ Vero E6/ Calu-3/ proteome 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.15.444275; this version posted June 24, 2021.